SCHEMBL7537524

SCHEMBL7537524

CCOC(=O)C(N)C(C(=O)CC)c1ccc(NC(=O)c2csc(NC(=O)NCc3ccccc3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
NAMPT P43490 2/20 0.43
RAB9A P51151 6/20 0.42
NPC1 O15118 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ROCK2 O75116 3/20 0.42
ROCK1 Q13464 3/20 0.42
LMNA P02545 4/20 0.41
TP53 P04637 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HSP90AA1 P07900 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
EGFR P00533 1/20 0.40
KDR P35968 1/20 0.38
GAA P10253 2/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7145903 0.92 ROCK2 (0.44) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7143549 0.84 LMNA (0.46) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7147820 0.82 LMNA (0.48) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7138766 0.81 LMNA (0.44) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7136553 0.80 LMNA (0.50) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7142296 0.79 ROCK2 (0.48) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7537521 0.78 MAPT (0.47) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7145101 0.78 ITGB3 (0.48) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL6881918 0.77 MAPT (0.47) MAPTNAMPTRAB9ANPC1SMN1; SMN2
SCHEMBL7146575 0.77 ROCK2 (0.50) MAPTNAMPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 MAPT 86/4885NAMPT 809/4885RAB9A 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.